|Other names||Candidosis, moniliasis, oidiomycosis|
|Oral candidiasis (thrush)|
|Symptoms||White patches or vaginal discharge, itchy|
|Causes||Candida (a type of yeast)|
|Risk factors||Immunosuppression (HIV/AIDS), diabetes, corticosteroids, antibiotic therapy|
|Medication||Clotrimazole, nystatin, fluconazole|
|Frequency||6% of babies (mouth) 75% of women at some time (vaginal)|
Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the mouth, in some countries it is commonly called thrush. Signs and symptoms include white patches on the tongue or other areas of the mouth and throat. Other symptoms may include soreness and problems swallowing. When it affects the vagina, it may be referred to as a yeast infection or thrush. Signs and symptoms include genital itching, burning, and sometimes a white "cottage cheese-like" discharge from the vagina. Yeast infections of the penis are less common and typically present with an itchy rash. Very rarely, yeast infections may become invasive, spreading to other parts of the body. This may result in fevers along with other symptoms depending on the parts involved.
More than 20 types of Candida can cause infection with Candida albicans being the most common. Infections of the mouth are most common among children less than one month old, the elderly, and those with weak immune systems. Conditions that result in a weak immune system include HIV/AIDS, the medications used after organ transplantation, diabetes, and the use of corticosteroids. Other risks include dentures, following antibiotic therapy, and breastfeeding. Vaginal infections occur more commonly during pregnancy, in those with weak immune systems, and following antibiotic use. Individuals at risk for invasive candidiasis include low birth weight babies, people recovering from surgery, people admitted to intensive care units, and those with an otherwise compromised immune system.
Efforts to prevent infections of the mouth include the use of chlorhexidine mouthwash in those with poor immune function and washing out the mouth following the use of inhaled steroids. Little evidence supports probiotics for either prevention or treatment, even among those with frequent vaginal infections. For infections of the mouth, treatment with topical clotrimazole or nystatin is usually effective. Oral or intravenous fluconazole, itraconazole, or amphotericin B may be used if these do not work. A number of topical antifungal medications may be used for vaginal infections, including clotrimazole. In those with widespread disease, an echinocandin such as caspofungin or micafungin is used. A number of weeks of intravenous amphotericin B may be used as an alternative. In certain groups at very high risk, antifungal medications may be used preventatively.
Infections of the mouth occur in about 6% of babies less than a month old. About 20% of those receiving chemotherapy for cancer and 20% of those with AIDS also develop the disease. About three-quarters of women have at least one yeast infection at some time during their lives. Widespread disease is rare except in those who have risk factors.
Signs and symptoms
Signs and symptoms of candidiasis vary depending on the area affected. Most candidal infections result in minimal complications such as redness, itching, and discomfort, though complications may be severe or even fatal if left untreated in certain populations. In healthy (immunocompetent) persons, candidiasis is usually a localized infection of the skin, fingernails or toenails (onychomycosis), or mucosal membranes, including the oral cavity and pharynx (thrush), esophagus, and the genitalia (vagina, penis, etc.); less commonly in healthy individuals, the gastrointestinal tract, urinary tract, and respiratory tract are sites of candida infection.
In immunocompromised individuals, Candida infections in the esophagus occur more frequently than in healthy individuals and have a higher potential of becoming systemic, causing a much more serious condition, a fungemia called candidemia. Symptoms of esophageal candidiasis include difficulty swallowing, painful swallowing, abdominal pain, nausea, and vomiting.
Infection in the mouth is characterized by white discolorations in the tongue, around the mouth, and throat. Irritation may also occur, causing discomfort when swallowing.
Thrush is commonly seen in infants. It is not considered abnormal in infants unless it lasts longer than a few weeks.
Infection of the vagina or vulva may cause severe itching, burning, soreness, irritation, and a whitish or whitish-gray cottage cheese-like discharge. Symptoms of infection of the male genitalia (balanitis thrush) include red skin around the head of the penis, swelling, irritation, itchiness and soreness of the head of the penis, thick, lumpy discharge under the foreskin, unpleasant odour, difficulty retracting the foreskin (phimosis), and pain when passing urine or during sex.
Signs and symptoms of candidiasis in the skin include itching, irritation, and chafing or broken skin.
Common symptoms of gastrointestinal candidiasis in healthy individuals are anal itching, belching, bloating, indigestion, nausea, diarrhea, gas, intestinal cramps, vomiting, and gastric ulcers. Perianal candidiasis can cause anal itching; the lesion can be red, papular, or ulcerative in appearance, and it is not considered to be a sexually transmissible disease. Abnormal proliferation of the candida in the gut may lead to dysbiosis. While it is not yet clear, this alteration may be the source of symptoms generally described as the irritable bowel syndrome, and other gastrointestinal diseases.
Candida yeasts are generally present in healthy humans, frequently part of the human body's normal oral and intestinal flora, and particularly on the skin; however, their growth is normally limited by the human immune system and by competition of other microorganisms, such as bacteria occupying the same locations in the human body. Candida requires moisture for growth, notably on the skin. For example, wearing wet swimwear for long periods of time is believed to be a risk factor. Candida can also cause diaper rashes in babies. In extreme cases, superficial infections of the skin or mucous membranes may enter the bloodstream and cause systemic Candida infections.
Factors that increase the risk of candidiasis include HIV/AIDS, mononucleosis, cancer treatments, steroids, stress, antibiotic usage, diabetes, and nutrient deficiency. Hormone replacement therapy and infertility treatments may also be predisposing factors. Use of inhaled corticosteroids increases risk of candidiasis of the mouth. Inhaled corticosteroids with other risk factors such as antibiotics, oral glucocorticoids, not rinsing mouth after use of inhaled corticosteroids or high dose of inhaled corticosteroids put people at even higher risk. Treatment with antibiotics can lead to eliminating the yeast's natural competitors for resources in the oral and intestinal flora, thereby increasing the severity of the condition. A weakened or undeveloped immune system or metabolic illnesses are significant predisposing factors of candidiasis. Almost 15% of people with weakened immune systems develop a systemic illness caused by Candida species. Diets high in simple carbohydrates have been found to affect rates of oral candidiases.
C. albicans was isolated from the vaginas of 19% of apparently healthy women, i.e., those who experienced few or no symptoms of infection. External use of detergents or douches or internal disturbances (hormonal or physiological) can perturb the normal vaginal flora, consisting of lactic acid bacteria, such as lactobacilli, and result in an overgrowth of Candida cells, causing symptoms of infection, such as local inflammation. Pregnancy and the use of oral contraceptives have been reported as risk factors. Diabetes mellitus and the use of antibiotics are also linked to increased rates of yeast infections.
In penile candidiasis, the causes include sexual intercourse with an infected individual, low immunity, antibiotics, and diabetes. Male genital yeast infections are less common, but a yeast infection on the penis caused from direct contact via sexual intercourse with an infected partner is not uncommon.
Breast-feeding mothers may also develop candidiasis on and around the nipple as a result of moisture created by excessive milk-production.
In oral candidiasis, simply inspecting the person's mouth for white patches and irritation may make the diagnosis. A sample of the infected area may also be taken to determine what organism is causing the infection.
Symptoms of vaginal candidiasis are also present in the more common bacterial vaginosis; aerobic vaginitis is distinct and should be excluded in the differential diagnosis. In a 2002 study, only 33% of women who were self-treating for a yeast infection actually had such an infection, while most had either bacterial vaginosis or a mixed-type infection.
Diagnosis of a yeast infection is done either via microscopic examination or culturing. For identification by light microscopy, a scraping or swab of the affected area is placed on a microscope slide. A single drop of 10% potassium hydroxide (KOH) solution is then added to the specimen. The KOH dissolves the skin cells, but leaves the Candida cells intact, permitting visualization of pseudohyphae and budding yeast cells typical of many Candida species.
For the culturing method, a sterile swab is rubbed on the infected skin surface. The swab is then streaked on a culture medium. The culture is incubated at 37 °C (98.6 °F) for several days, to allow development of yeast or bacterial colonies. The characteristics (such as morphology and colour) of the colonies may allow initial diagnosis of the organism causing disease symptoms. Respiratory, gastrointestinal, and esophageal candidiasis require an endoscopy to diagnose. For gastrointestinal candidiasis, it is necessary to obtain a 3–5 milliliter sample of fluid from the duodenum for fungal culture. The diagnosis of gastrointestinal candidiasis is based upon the culture containing in excess of 1,000 colony-forming units per milliliter.
Candidiasis may be divided into these types:
- Mucosal candidiasis
- Oral candidiasis (thrush, oropharyngeal candidiasis)
- Pseudomembranous candidiasis
- Erythematous candidiasis
- Hyperplastic candidiasis
- Denture-related stomatitis — Candida organisms are involved in about 90% of cases
- Angular cheilitis — Candida species are responsible for about 20% of cases, mixed infection of C. albicans and Staphylococcus aureus for about 60% of cases.
- Median rhomboid glossitis
- Candidal vulvovaginitis (vaginal yeast infection)
- Candidal balanitis — infection of the glans penis, almost exclusively occurring in uncircumcised males
- Esophageal candidiasis (candidal esophagitis)
- Gastrointestinal candidiasis
- Respiratory candidiasis
- Oral candidiasis (thrush, oropharyngeal candidiasis)
- Cutaneous candidiasis
- Candidial folliculitis
- Candidal intertrigo
- Candidal paronychia
- Perianal candidiasis, may present as pruritus ani:309
- Chronic mucocutaneous candidiasis
- Congenital cutaneous candidiasis
- Diaper candidiasis: an infection of a child's diaper area:309
- Erosio interdigitalis blastomycetica
- Candidial onychomycosis (nail infection) caused by Candida
- Systemic candidiasis
- Antibiotic candidiasis (iatrogenic candidiasis)
A diet that supports the immune system and is not high in simple carbohydrates contributes to a healthy balance of the oral and intestinal flora. While yeast infections are associated with diabetes, the level of blood sugar control may not affect the risk. Wearing cotton underwear may help to reduce the risk of developing skin and vaginal yeast infections, along with not wearing wet clothes for long periods of time. For women who experience recurrent yeast infections, there is limited evidence that oral or intravaginal probiotics help to prevent future infections. This includes either as pills or as yogurt.
Oral hygiene can help prevent oral candidiasis when people have a weakened immune system. For people undergoing cancer treatment, chlorhexidine mouthwash can prevent or reduce thrush. People who use inhaled corticosteroids can reduce the risk of developing oral candidiasis by rinsing the mouth with water or mouthwash after using the inhaler. People with dentures should also disinfect their dentures regularly to prevent oral candidiasis.
Candidiasis is treated with antifungal medications; these include clotrimazole, nystatin, fluconazole, voriconazole, amphotericin B, and echinocandins. Intravenous fluconazole or an intravenous echinocandin such as caspofungin are commonly used to treat immunocompromised or critically ill individuals.
The 2016 revision of the clinical practice guideline for the management of candidiasis lists a large number of specific treatment regimens for Candida infections that involve different Candida species, forms of antifungal drug resistance, immune statuses, and infection localization and severity. Gastrointestinal candidiasis in immunocompetent individuals is treated with 100–200 mg fluconazole per day for 2–3 weeks.
Mouth and throat candidiasis are treated with antifungal medication. Oral candidiasis usually responds to topical treatments; otherwise, systemic antifungal medication may be needed for oral infections. Candidal skin infections in the skin folds (candidal intertrigo) typically respond well to topical antifungal treatments (e.g., nystatin or miconazole). For breastfeeding mothers topical miconazole is the most effective treatment for treating candidiasis on the breasts. Gentian violet can be used for thrush in breastfeeding babies. Systemic treatment with antifungals by mouth is reserved for severe cases or if treatment with topical therapy is unsuccessful. Candida esophagitis may be treated orally or intravenously; for severe or azole-resistant esophageal candidiasis, treatment with amphotericin B may be necessary.
Vaginal yeast infections are typically treated with topical antifungal agents. Penile yeast infections are also treated with antifungal agents, but while an internal treatment may be used (such as a pessary) for vaginal yeast infections, only external treatments – such as a cream – can be recommended for penile treatment. A one-time dose of fluconazole by mouth is 90% effective in treating a vaginal yeast infection. For severe nonrecurring cases, several doses of fluconazole is recommended. Local treatment may include vaginal suppositories or medicated douches. Other types of yeast infections require different dosing. C. albicans can develop resistance to fluconazole, this being more of an issue in those with HIV/AIDS who are often treated with multiple courses of fluconazole for recurrent oral infections.
For vaginal yeast infection in pregnancy, topical imidazole or triazole antifungals are considered the therapy of choice owing to available safety data. Systemic absorption of these topical formulations is minimal, posing little risk of transplacental transfer. In vaginal yeast infection in pregnancy, treatment with topical azole antifungals is recommended for 7 days instead of a shorter duration.
Treatment typically consists of oral or intravenous antifungal medications. In candidal infections of the blood, intravenous fluconazole or an echinocandin such as caspofungin may be used. Amphotericin B is another option.
Oral candidiasis is the most common fungal infection of the mouth, and it also represents the most common opportunistic oral infection in humans. Infections of the mouth occur in about 6% of babies less than a month old. About 20% of those receiving chemotherapy for cancer and 20% of those with AIDS also develop the disease.
It is estimated that 20% of women may be asymptomatically colonized by vaginal yeast. In the United States there are approximately 1.4 million doctor office visits every year for candidiasis. About three-quarters of women have at least one yeast infection at some time during their lives.
Esophageal candidiasis is the most common esophageal infection in persons with AIDS and accounts for about 50% of all esophageal infections, often coexisting with other esophageal diseases. About two-thirds of people with AIDS and esophageal candidiasis also have oral candidiasis.
Candidal sepsis is rare. Candida is the fourth most common cause of bloodstream infections among hospital patients in the United States. The incidence of bloodstream candida in intensive care units varies widely between countries.
The colloquial term "thrush" refers to the resemblance of the white flecks present in some forms of candidiasis (e.g. pseudomembranous candidiasis) with the breast of the bird of the same name. The term candidosis is largely used in British English, and candidiasis in American English. Candida is also pronounced differently; in American English, the stress is on the "i", whereas in British English the stress is on the first syllable.
The genus Candida and species C. albicans were described by botanist Christine Marie Berkhout in her doctoral thesis at the University of Utrecht in 1923. Over the years, the classification of the genera and species has evolved. Obsolete names for this genus include Mycotorula and Torulopsis. The species has also been known in the past as Monilia albicans and Oidium albicans. The current classification is nomen conservandum, which means the name is authorized for use by the International Botanical Congress (IBC).
The genus Candida includes about 150 different species; however, only a few are known to cause human infections. C. albicans is the most significant pathogenic species. Other species pathogenic in humans include C. auris, C. tropicalis, C. glabrata, C. krusei, C. parapsilosis, C. dubliniensis, and C. lusitaniae.
The name Candida was proposed by Berkhout. It is from the Latin word toga candida, referring to the white toga (robe) worn by candidates for the Senate of the ancient Roman republic. The specific epithet albicans also comes from Latin, albicare meaning "to whiten". These names refer to the generally white appearance of Candida species when cultured.
A 2005 publication noted that "a large pseudoscientific cult" has developed around the topic of Candida, with claims stating that up to one in three people are affected by yeast-related illness, particularly a condition called "Candidiasis hypersensitivity". Some practitioners of alternative medicine have promoted these purported conditions and sold dietary supplements as supposed cures; a number of them have been prosecuted. In 1990, alternative health vendor Nature's Way signed an FTC consent agreement not to misrepresent in advertising any self-diagnostic test concerning yeast conditions or to make any unsubstantiated representation concerning any food or supplement's ability to control yeast conditions, with a fine of $30,000 payable to the National Institutes of Health for research in genuine candidiasis.
- James WD, Elston DM, Berger TG, Andrews GC, et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. pp. 308–311. ISBN 978-0-7216-2921-6.
- "Vaginal Candidiasis". Fungal Diseases. United States: Centers for Disease Control and Prevention. 13 November 2019. Retrieved 24 Dec 2019.
- "Candida infections of the mouth, throat, and esophagus". Fungal Diseases. United States: Centers for Disease Control and Prevention. 13 November 2019. Retrieved 24 Dec 2019.
- "Candidiasis". Fungal Diseases. United States: Centers for Disease Control and Prevention. 13 November 2019. Retrieved 24 Dec 2019.
- "Risk & Prevention". cdc.gov. February 13, 2014. Retrieved 28 December 2014.
- "Treatment & Outcomes of Oral Candidiasis". cdc.gov. February 13, 2014. Retrieved 28 December 2014.
- "Oral Candidiasis Statistics". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- "Genital / vulvovaginal candidiasis (VVC)". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- "Symptoms of Oral Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- "Thrush in men and women". nhs.uk. 9 January 2018. Retrieved 16 March 2020.
- "Symptoms of Genital / Vulvovaginal Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- "Symptoms of Invasive Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- "Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- Walker M (2008). "Conquering common breast-feeding problems". The Journal of Perinatal & Neonatal Nursing. 22 (4): 267–74. doi:10.1097/01.JPN.0000341356.45446.23. PMID 19011490. S2CID 27801867.
- "People at Risk for Genital / Vulvovaginal Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- "People at Risk for Invasive Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- Jurden L, Buchanan M, Kelsberg G, Safranek S (June 2012). "Clinical inquiries. Can probiotics safely prevent recurrent vaginitis?". The Journal of Family Practice. 61 (6): 357, 368. PMID 22670239.
- Abad CL, Safdar N (June 2009). "The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review". Journal of Chemotherapy. 21 (3): 243–52. doi:10.1179/joc.2009.21.3.243. PMID 19567343. S2CID 32398416.
- "Treatment & Outcomes of Genital / Vulvovaginal Candidiasis". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. (February 2016). "Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases. 62 (4): 409–17. doi:10.1093/cid/civ1194. PMID 26810419.
- "Invasive Candidiasis Statistics". cdc.gov. February 13, 2014. Archived from the original on 29 December 2014. Retrieved 28 December 2014.
- Dolin GL, Mandell JE, Bennett R (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases (7th ed.). Philadelphia, PA: Churchill Livingstone/Elsevier. pp. Chapter 250. ISBN 978-0-443-06839-3.
- Hidalgo JA, Vazquez JA (18 August 2015). "Candidiasis: Clinical Presentation". Medscape. WebMD. Archived from the original on 1 June 2016. Retrieved 22 June 2016.
- Walsh TJ, Dixon DM (1996). "Deep Mycoses". In Baron S, et al. (eds.). Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 978-0-9631172-1-2. Archived from the original on 2008-12-01.
- Patil S, Rao RS, Majumdar B, Anil S (December 2015). "Clinical Appearance of Oral Candida Infection and Therapeutic Strategies". Frontiers in Microbiology. 6: 1391. doi:10.3389/fmicb.2015.01391. PMC 4681845. PMID 26733948.
- Martins N, Ferreira IC, Barros L, Silva S, Henriques M (June 2014). "Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment" (PDF). Mycopathologia. 177 (5–6): 223–40. doi:10.1007/s11046-014-9749-1. hdl:10198/10147. PMID 24789109. S2CID 795450.
Candida species and other microorganisms are involved in this complicated fungal infection, but Candida albicans continues to be the most prevalent. In the past two decades, it has been observed an abnormal overgrowth in the gastrointestinal, urinary and respiratory tracts, not only in immunocompromised patients but also related to nosocomial infections and even in healthy individuals. There is a wide variety of causal factors that contribute to yeast infection which means that candidiasis is a good example of a multifactorial syndrome.
- Wang ZK, Yang YS, Stefka AT, Sun G, Peng LH (April 2014). "Review article: fungal microbiota and digestive diseases". Alimentary Pharmacology & Therapeutics. 39 (8): 751–66. doi:10.1111/apt.12665. PMID 24612332. S2CID 22101484.
In addition, GI fungal infection is reported even among those patients with normal immune status. Digestive system-related fungal infections may be induced by both commensal opportunistic fungi and exogenous pathogenic fungi. The IFI in different GI sites have their special clinical features, which are often accompanied by various severe diseases. Although IFI associated with digestive diseases are less common, they can induce fatal outcomes due to less specificity of related symptoms, signs, endoscopic and imaging manifestations, and the poor treatment options. ... Candida sp. is also the most frequently identified species among patients with gastric IFI. ... Gastric IFI is often characterised by the abdominal pain and vomiting and with the endoscopic characteristics including gastric giant and multiple ulcers, stenosis, perforation, and fistula. For example, gastric ulcers combined with entogastric fungal infection, characterised by deep, large and intractable ulcers, were reported as early as the 1930s. ... The overgrowth and colonisation of fungi in intestine can lead to diarrhoea.
- Erdogan A, Rao SS (April 2015). "Small intestinal fungal overgrowth". Current Gastroenterology Reports. 17 (4): 16. doi:10.1007/s11894-015-0436-2. PMID 25786900. S2CID 3098136.
Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. ... For routine SIFO in an immunocompetent host, a 2–3 week oral course of fluconazole 100–200 mg will suffice.
- Fidel PL (2002). "Immunity to Candida". Oral Diseases. 8 Suppl 2: 69–75. doi:10.1034/j.1601-0825.2002.00015.x. PMID 12164664.
- Pappas PG (September 2006). "Invasive candidiasis". Infectious Disease Clinics of North America. 20 (3): 485–506. doi:10.1016/j.idc.2006.07.004. PMID 16984866.
- Yamada T, Alpers DH, et al. (2009). Textbook of gastroenterology (5th ed.). Chichester, West Sussex: Blackwell Pub. p. 814. ISBN 978-1-4051-6911-0.
- "Candida infections of the mouth, throat, and esophagus | Fungal Diseases | CDC". www.cdc.gov. 2019-04-17. Retrieved 2019-08-01.
- "Thrush". 2011. Archived from the original on 2011-02-10. Retrieved 2011-04-08.
- NHS: Symptoms of thrush in men (balanitis thrush) Archived 2013-11-01 at the Wayback Machine
- "Candida infection of the skin: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2019-08-06.
- Wolff BG, et al., eds. (2007). The ASCRS textbook of colon and rectal surgery. New York: Springer. pp. 241, 242, 245. ISBN 978-0-387-24846-2.
- Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA (February 2015). "Mycobiota in gastrointestinal diseases". Nature Reviews. Gastroenterology & Hepatology. 12 (2): 77–87. doi:10.1038/nrgastro.2014.188. PMID 25385227. S2CID 5370536.
- Santelmann H, Howard JM (January 2005). "Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome" (PDF). European Journal of Gastroenterology & Hepatology. 17 (1): 21–6. CiteSeerX 10.1.1.567.6030. doi:10.1097/00042737-200501000-00005. PMID 15647635. S2CID 35882838.
- Collins SM (August 2014). "A role for the gut microbiota in IBS". Nature Reviews. Gastroenterology & Hepatology. 11 (8): 497–505. doi:10.1038/nrgastro.2014.40. PMID 24751910. S2CID 10676400.
- Gouba N, Drancourt M (2015). "Digestive tract mycobiota: a source of infection". Médecine et Maladies Infectieuses. 45 (1–2): 9–16. doi:10.1016/j.medmal.2015.01.007. PMID 25684583.
- Mulley AG, Goroll AH (2006). Primary Care Medicine: office evaluation and management of the adult patient. Philadelphia: Wolters Kluwer Health. pp. 802–3. ISBN 978-0-7817-7456-7. Retrieved 2008-11-23.
- Goehring RV (2008). Mims' medical microbiology (4th ed.). Philadelphia, PA: Mosby Elsevier. p. 656. ISBN 978-0-323-04475-2.
- MedlinePlus Encyclopedia: Vaginal yeast infection
- Nwokolo NC, Boag FC (May 2000). "Chronic vaginal candidiasis. Management in the postmenopausal patient". Drugs & Aging. 16 (5): 335–9. doi:10.2165/00002512-200016050-00003. PMID 10917071. S2CID 24662417.
- Saag KG, Furst ME, Barnes PJ. "Major side effects of inhaled glucocorticoids". UpToDate. Retrieved 2019-08-02.
- Bassetti M, Mikulska M, Viscoli C (December 2010). "Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit". Critical Care. 14 (6): 244. doi:10.1186/cc9239. PMC 3220045. PMID 21144007.
- Odds FC (1987). "Candida infections: an overview". Critical Reviews in Microbiology. 15 (1): 1–5. doi:10.3109/10408418709104444. PMID 3319417.
- Choo ZW, Chakravarthi S, Wong SF, Nagaraja HS, Thanikachalam PM, Mak JW, et al. (January 2010). "A comparative histopathological study of systemic candidiasis in association with experimentally induced breast cancer". Oncology Letters. 1 (1): 215–222. doi:10.3892/ol_00000039. PMC 3436220. PMID 22966285. Archived from the original on 2011-07-16.
- Akpan A, Morgan R (August 2002). "Oral candidiasis". Postgraduate Medical Journal. 78 (922): 455–9. doi:10.1136/pmj.78.922.455. PMC 1742467. PMID 12185216.
- Mårdh PA, Novikova N, Stukalova E (October 2003). "Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis". BJOG. 110 (10): 934–7. doi:10.1111/j.1471-0528.2003.01445.x. PMID 14550364. S2CID 25585573.
- Schiefer HG (1997). "Mycoses of the urogenital tract". Mycoses. 40 Suppl 2 (Suppl 2): 33–6. doi:10.1111/j.1439-0507.1997.tb00561.x. PMID 9476502. S2CID 27268821.
- David LM, Walzman M, Rajamanoharan S (October 1997). "Genital colonisation and infection with candida in heterosexual and homosexual males". Genitourinary Medicine. 73 (5): 394–6. doi:10.1136/sti.73.5.394. PMC 1195901. PMID 9534752.
- Skoczylas MM, Walat A, Kordek A, Loniewska B, Rudnicki J, Maleszka R, Torbé A (2014). "Congenital candidiasis as a subject of research in medicine and human ecology". Annals of Parasitology. 60 (3): 179–89. PMID 25281815.
- "Oral thrush - Diagnosis and treatment - Mayo Clinic". www.mayoclinic.org. Retrieved 2019-08-06.
- Warren T (2010). "Is It a Yeast Infection?". Archived from the original on 2011-02-25. Retrieved 2011-02-23.
- Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (January 2002). "Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis". BJOG. 109 (1): 34–43. doi:10.1111/j.1471-0528.2002.00432.x. hdl:10067/1033820151162165141. PMID 11845812. S2CID 8304009.
- Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS (March 2002). "Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis". Obstetrics and Gynecology. 99 (3): 419–25. doi:10.1016/S0029-7844(01)01759-8. PMID 11864668. S2CID 25895596.
- Guarner, J.; Brandt, M. E. (2011-04-01). "Histopathologic Diagnosis of Fungal Infections in the 21st Century". Clinical Microbiology Reviews. American Society for Microbiology. 24 (2): 247–280. doi:10.1128/cmr.00053-10. ISSN 0893-8512. PMC 3122495. PMID 21482725.
- Hidalgo JA, Vazquez JA (18 August 2015). "Candidiasis: Workup". Medscape. WebMD. Archived from the original on 11 June 2016. Retrieved 22 June 2016.
- Mastromarino P, Vitali B, Mosca L (July 2013). "Bacterial vaginosis: a review on clinical trials with probiotics" (PDF). The New Microbiologica. 36 (3): 229–38. PMID 23912864. Archived (PDF) from the original on 2015-05-18.
- Nyirjesy P, Sobel JD (May 2013). "Genital mycotic infections in patients with diabetes". Postgraduate Medicine. 125 (3): 33–46. doi:10.3810/pgm.2013.05.2650. PMID 23748505. S2CID 25586978.
- Nolting S, Brautigam M, Weidinger G (April 1994). "Terbinafine in onychomycosis with involvement by non-dermatophytic fungi". The British Journal of Dermatology. 130 Suppl 43: 16–21. doi:10.1111/j.1365-2133.1994.tb06088.x. PMID 8186136. S2CID 37415499.
- Reiss E, Shadomy HJ, Lyon GM (2011). "Chapter 11". Fundamental medical mycology. Hoboken, N.J.: John Wiley & Sons. ISBN 978-1-118-10176-6. Archived from the original on 2016-04-30.
- Mobley DP, Cappelli CC (2008). Prevention in clinical oral health care. St. Louis, Mo.: Mosby Elsevier. p. 254. ISBN 9780323036955. Archived from the original on 2017-09-06.
- Falagas ME, Betsi GI, Athanasiou S (August 2006). "Probiotics for prevention of recurrent vulvovaginal candidiasis: a review". The Journal of Antimicrobial Chemotherapy. 58 (2): 266–72. doi:10.1093/jac/dkl246. PMID 16790461.
Thus, the available evidence for the use of probiotics for prevention of recurrent VVC is limited
- Walker, Marsha (2008). "Conquering Common Breast-feeding Problems". The Journal of Perinatal & Neonatal Nursing. 22 (4): 267–274. doi:10.1097/01.JPN.0000341356.45446.23. ISSN 0893-2190. PMID 19011490. S2CID 27801867.
- "Male thrush: everything you need to know". medino. Retrieved 2021-05-19.
- Moosa MY, Sobel JD, Elhalis H, Du W, Akins RA (January 2004). "Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium". Antimicrobial Agents and Chemotherapy. 48 (1): 161–7. doi:10.1128/AAC.48.1.161-167.2004. PMC 310176. PMID 14693534.
- Morschhäuser J (July 2002). "The genetic basis of fluconazole resistance development in Candida albicans". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1587 (2–3): 240–8. doi:10.1016/s0925-4439(02)00087-x. PMID 12084466.
- Soong D, Einarson A (March 2009). "Vaginal yeast infections during pregnancy". Canadian Family Physician. 55 (3): 255–6. PMC 2654841. PMID 19282531.
- Felix TC, de Brito Röder DV, Dos Santos Pedroso R (March 2019). "Alternative and complementary therapies for vulvovaginal candidiasis". Folia Microbiologica. 64 (2): 133–141. doi:10.1007/s12223-018-0652-x. PMID 30269301. S2CID 52889140.
- "Systemic candidiasis". NIH.gov. U.S. DHHS, National Institute of Health. Oct 2014. Archived from the original on April 27, 2015. Retrieved April 19, 2015.
- Williams D, Lewis M (January 2011). "Pathogenesis and treatment of oral candidosis". Journal of Oral Microbiology. 3: 5771. doi:10.3402/jom.v3i0.5771. PMC 3087208. PMID 21547018.
- Bouquot BW, Neville DD, Damm CM, Allen JE (2002). Oral & maxillofacial pathology (2. ed.). Philadelphia: W.B. Saunders. pp. 189–197. ISBN 978-0-7216-9003-2.
- Lalla RV, Patton LL, Dongari-Bagtzoglou A (April 2013). "Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies". Journal of the California Dental Association. 41 (4): 263–8. PMID 23705242.
- Sobel JD (2007). "Vulvovaginal candidosis". The Lancet. 369 (9577): 1961–1971. doi:10.1016/s0140-6736(07)60917-9. ISSN 0140-6736. PMID 17560449. S2CID 33894309.
- Benedict K, Jackson BR, Chiller T, Beer KD (May 2019). "Estimation of Direct Healthcare Costs of Fungal Diseases in the United States". Clinical Infectious Diseases. 68 (11): 1791–1797. doi:10.1093/cid/ciy776. PMC 6409199. PMID 30204844.
- Gow NA (8 May 2002). "Candida albicans - a fungal Dr Jekyll and Mr Hyde" (PDF). Mycologist. 16 (1). doi:10.1017/S0269915X02006183. S2CID 86182033. Archived from the original (PDF) on 10 February 2020.
- "Candida" (PDF). CDC.gov. Center of Disease Control. Archived (PDF) from the original on April 27, 2015. Retrieved April 19, 2015.
- Vallabhaneni, Snigdha; Mody, Rajal K.; Walker, Tiffany; Chiller, Tom (2016). "1. The global burden of fungal disease". In Sobel, Jack; Ostrosky-Zeichner, Luis (eds.). Fungal Infections, An Issue of Infectious Disease Clinics of North America. Philadelphia: Elsevier. pp. 2–3. ISBN 978-0-323-41649-8.
- Lynch DP (August 1994). "Oral candidiasis. History, classification, and clinical presentation". Oral Surgery, Oral Medicine, and Oral Pathology. 78 (2): 189–93. doi:10.1016/0030-4220(94)90146-5. PMID 7936588.
- Obladen M (2012). "Thrush - nightmare of the foundling hospitals". Neonatology. 101 (3): 159–65. doi:10.1159/000329879. PMID 22024688. S2CID 5277114.
- Scully C (2018-09-24). "Mucosal Candidiasis". Medscape. WebMD LLC. Archived from the original on 2 November 2013. Retrieved 8 September 2013.
- Greuter W, McNeill J, Burdet HM, Barrie FR (2000). International Code of Botanical Nomenclature. Königstein. ISBN 978-3-904144-22-3. Archived from the original on 2008-12-02. Retrieved 2008-11-23.
- Odds FC (1987). "Candida infections: an overview". Critical Reviews in Microbiology. 15 (1): 1–5. doi:10.3109/10408418709104444. PMID 3319417.
- Barrett S (October 8, 2005). "Dubious "Yeast Allergies"". Quackwatch. Archived from the original on May 13, 2008.
- Jarvis WT. "Candidiasis Hypersensitivity". National Council Against Health Fraud. Retrieved 18 January 2014.
- Kumamoto CA (August 2011). "Inflammation and gastrointestinal Candida colonization". Current Opinion in Microbiology. 14 (4): 386–91. doi:10.1016/j.mib.2011.07.015. PMC 3163673. PMID 21802979.
- Gerard R, Sendid B, Colombel JF, Poulain D, Jouault T (June 2015). "An immunological link between Candida albicans colonization and Crohn's disease". Critical Reviews in Microbiology. 41 (2): 135–9. doi:10.3109/1040841X.2013.810587. PMID 23855357. S2CID 39349854.
- "Growing resistance to antifungal drugs 'a global issue'". BBC News. 17 May 2018. Retrieved 18 May 2018.
- Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ (May 2018). "Invasive candidiasis". Nature Reviews. Disease Primers. 4: 18026. doi:10.1038/nrdp.2018.26. PMID 29749387. S2CID 12502541.